peopleInnovationCareers RarePipelineCollaborationFinanceAdvance treatment Skip to main contentSkip to navigationSkip to search
HNSA   ( ,  %) SEK
Quotes are delayed 15 minutes

Increase of the number of shares and votes in Hansa Biopharma AB

30 Dec 2021, 08:00
Regulatory information

Lund, Sweden, December 30, 2021. Hansa Biopharma AB Hansa” or “the Company”, (Nasdaq Stockholm: HNSA), the pioneer enzyme technology for rare immunological conditions, today announces that the Company’s registered share capital and number of outstanding shares and votes have increased during the month of December 2021.

As previously announced on 12 December 2021, Hansa Biopharma’s board of directors resolved to issue 440,452 class C shares, by virtue of the authorization by the annual general meeting held on 12 May 2021. The class C shares do not entitle to dividends and each share entitles to 1/10 voting right.

The purpose of the share issue and the repurchase of the issued shares is to enable potential future delivery of ordinary shares in accordance with long term incentive programs based on employee stock options adopted by the annual general meeting held on 23 June 2020 and the annual general meeting held on 12 May 2021 as well as to cover any social charges associated with the mentioned, or other outstanding, programs. All class C shares are owned by the Company.

As of today, the total number of registered and outstanding shares of the Company amounts to 46,335,361, whereof 44,473,452 are ordinary shares and 1,861,909 are class C shares. As of today, the number of votes in the Company amounts to 44,659,642.9, and the registered share capital amounts to SEK 46,335,361.

For further information, please contact:
Klaus Sindahl, Head of Investor Relations
Hansa Biopharma 
Mobile: +46 (0) 709-298 269

Katja Margell
Head of Corporate Communications 
Hansa Biopharma 
Mobile: +46 (0) 768-198 326

About Hansa Biopharma
Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa has developed a first-in-class immunoglobulin G (IgG) antibody cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients. Hansa has a rich and expanding research and development program, based on the Company’s proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in transplantation, autoimmune diseases, gene therapy and cancer. Hansa Biopharma is based in Lund, Sweden and has operations in Europe and the U.S. The Company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at